Medical treatment of diabetic retinopathy with somatostatin analogues

Stela S. Palii, Sergio Caballero, Gideon Shapiro, Maria B. Grant

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Somatostatin
Octreotide
Laser Therapy
Pharmacology
Retinal Neovascularization
Retinal Vessels
Light Coagulation
Vision Disorders
Therapeutic Uses
Therapeutics
Clinical Trials
Pathology
Research

Keywords

  • Diabetic retinopathy
  • Neovascularisation
  • Octreotide
  • Somatostatin analogues
  • Somatostatin receptor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Medical treatment of diabetic retinopathy with somatostatin analogues. / Palii, Stela S.; Caballero, Sergio; Shapiro, Gideon; Grant, Maria B.

In: Expert Opinion on Investigational Drugs, Vol. 16, No. 1, 01.2007, p. 73-82.

Research output: Contribution to journalArticle

Palii, Stela S. ; Caballero, Sergio ; Shapiro, Gideon ; Grant, Maria B. / Medical treatment of diabetic retinopathy with somatostatin analogues. In: Expert Opinion on Investigational Drugs. 2007 ; Vol. 16, No. 1. pp. 73-82.
@article{90a67fe3213442ce90b751ae6ce3abd0,
title = "Medical treatment of diabetic retinopathy with somatostatin analogues",
abstract = "Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.",
keywords = "Diabetic retinopathy, Neovascularisation, Octreotide, Somatostatin analogues, Somatostatin receptor",
author = "Palii, {Stela S.} and Sergio Caballero and Gideon Shapiro and Grant, {Maria B.}",
year = "2007",
month = "1",
doi = "10.1517/13543784.16.1.73",
language = "English (US)",
volume = "16",
pages = "73--82",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Medical treatment of diabetic retinopathy with somatostatin analogues

AU - Palii, Stela S.

AU - Caballero, Sergio

AU - Shapiro, Gideon

AU - Grant, Maria B.

PY - 2007/1

Y1 - 2007/1

N2 - Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.

AB - Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.

KW - Diabetic retinopathy

KW - Neovascularisation

KW - Octreotide

KW - Somatostatin analogues

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=33845700582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845700582&partnerID=8YFLogxK

U2 - 10.1517/13543784.16.1.73

DO - 10.1517/13543784.16.1.73

M3 - Article

VL - 16

SP - 73

EP - 82

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 1

ER -